• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

Sanofi (Group) [since May 2011]

Sanofi-aventis is the world's third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organization, Sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine, and vaccines. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). *

 

	Start	2011-05-06 renamed
	Predecessor	Sanofi-Aventis (Group)
	Industry	pharmaceutical
	Person	Brandicourt, Olivier (Sanofi 201508 CEO before CEO of Bayer HealthCare before Pfizer Inc)
	Person 2	Contamine, Jérôme (Sanofi 2009–201809 CFO RETIRED 9/18)
	Region	Paris
	Country	France
	Street	174 avenue de France
	City	75635 Paris
	Tel	+33-1-5377-4000
		Address record changed: 2012-01-11
Basic data	Employees	I: 50,001 to 100,0 (2019-02-06)
	Currency	EUR
	Annual sales	34,463,000,000 (sales, net, consolidated (2018) 2018-12-31)
	Profit	4,410,000,000 (2018-12-31)
	Cash	2,633,000,000 (2018-12-31)
		* Document for �About Section�:
		Record changed: 2019-03-16

Advertisement

More documents for Sanofi (Group) [since May 2011]

• [1] Oxford BioMedica plc. (3/14/19). "Press Release: Oxford Biomedica plc Preliminary Results for the Year Ended 31 December 2018". Oxford....
• [2] New York Times [The Editorial Board]. (2/24/19). "News: It’s Time for Pharmaceutical Companies to Have Their Tobacco Moment"....
• [3] Sanofi S.A.. (2/12/19). "Press Release: Sanofi Appoints Ameet Nathwani Chief Digital Officer". Paris....
• [4] Sanofi S.A.. (2/7/19). "Press Release: Sanofi Delivers 2018 Business EPS Growth of 5.1% at CER". Paris....
• [5] Oxford BioMedica plc. (2/7/19). "Press Release: Oxford Biomedica Provides Update on Programmes Outlicensed to Sanofi". Oxford....
• [6] Sanofi S.A.. (2/6/19). "Press Release: FDA Approves Cablivi (caplacizumab-yhdp), the First Nanobody-based Medicine, for Adults with Acquired Thrombotic Thrombocytopenic Purpura (aTTP)". Paris....
• [7] Sanofi S.A.. (2/6/19). "Press Release: Sanofi’s Board of Directors Notes the Resignation of Christian Mulliez and Co-opts Christophe Babule as Director". Paris....
• [8] Sanofi S.A.. (2/5/19). "Press Release: Isatuximab Phase 3 Trial Meets Primary Endpoint of Prolonging Progression Free Survival in Patients with Relapsed/Refractory Multiple Myeloma". Paris....
• [9] Sanofi S.A.. (2/4/19). "Press Release: CHMP Recommends Approval of Praluent (alirocumab) to Reduce Cardiovascular Risk in People with Established Atherosclerotic Cardiovascular Disease". Paris & Tarrytown, NY....
• [10] Sanofi S.A.. (1/30/19). "Press Release: Fexinidazole, the First All-oral Treatment for Sleeping Sickness, Approved in Democratic Republic of Congo". Paris & Geneva....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Contact  |  The use of this website requires to accept the disclaimer!   |  A project of [iito] Business Intelligence © 2002-2019. Made in Germany.